|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.20 USD | +9.00% |
|
+14.29% | +33.02% |
| 06-30 | NovoCure Says Optune Pax Receives CE Mark for Locally Advanced Pancreatic Cancer Treatment | MT |
| 06-29 | NovoCure Limited(NasdaqGS:NVCR) added to Russell 2000 Value Benchmark | CI |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Bullish | Bullish |
| Resistance | 18.31 | 18.31 | 17.96 |
| Spread/Res. | -6.06% | -6.06% | -4.23% |
| Spread/Supp. | +32.10% | +32.10% | +25.82% |
| Support | 13.02 | 13.02 | 13.67 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- NVCR Stock
- Charts NovoCure Limited
Select your edition
All financial news and data tailored to specific country editions
